See more : Coca-Cola Europacific Partners PLC (CCEP.AS) Income Statement Analysis – Financial Results
Complete financial analysis of iCAD, Inc. (ICAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iCAD, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Liberty All-Star Growth Fund, Inc. (ASG) Income Statement Analysis – Financial Results
- Fulltech Fiber Glass Corp. (1815.TWO) Income Statement Analysis – Financial Results
- HF Company SA (ALHF.PA) Income Statement Analysis – Financial Results
- PGIM High Yield Bond Fund, Inc. (ISD) Income Statement Analysis – Financial Results
- Excelerate Energy, Inc. (EE) Income Statement Analysis – Financial Results
iCAD, Inc. (ICAD)
About iCAD, Inc.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.32M | 27.94M | 33.64M | 29.70M | 31.34M | 25.62M | 28.10M | 26.34M | 41.55M | 43.92M | 33.07M | 28.28M | 28.65M | 24.58M | 28.11M | 37.49M | 26.61M | 19.72M | 19.77M | 23.31M | 6.52M | 5.00M | 4.84M | 7.79M | 6.70M | 5.30M | 7.90M | 11.30M | 20.60M | 24.40M | 20.60M | 23.00M | 11.90M | 21.70M | 18.40M | 11.20M | 2.70M |
| Cost of Revenue | 2.78M | 8.13M | 9.40M | 8.34M | 7.11M | 6.19M | 9.93M | 7.82M | 12.20M | 12.70M | 9.98M | 8.24M | 8.63M | 3.15M | 4.62M | 6.18M | 5.26M | 4.29M | 4.64M | 6.53M | 2.94M | 5.16M | 3.94M | 5.27M | 4.50M | 3.40M | 4.90M | 7.10M | 12.00M | 13.50M | 11.70M | 10.40M | 6.90M | 12.10M | 12.10M | 7.60M | 7.10M |
| Gross Profit | 14.54M | 19.81M | 24.24M | 21.35M | 24.23M | 19.43M | 18.18M | 18.52M | 29.35M | 31.23M | 23.09M | 20.03M | 20.03M | 21.43M | 23.49M | 31.32M | 21.36M | 15.43M | 15.13M | 16.78M | 3.58M | -161.46K | 898.89K | 2.52M | 2.20M | 1.90M | 3.00M | 4.20M | 8.60M | 10.90M | 8.90M | 12.60M | 5.00M | 9.60M | 6.30M | 3.60M | -4.40M |
| Gross Profit Ratio | 83.94% | 70.90% | 72.07% | 71.90% | 77.30% | 75.84% | 64.68% | 70.31% | 70.63% | 71.09% | 69.81% | 70.84% | 69.90% | 87.20% | 83.56% | 83.53% | 80.25% | 78.24% | 76.55% | 71.97% | 54.88% | -3.23% | 18.59% | 32.38% | 32.84% | 35.85% | 37.97% | 37.17% | 41.75% | 44.67% | 43.20% | 54.78% | 42.02% | 44.24% | 34.24% | 32.14% | -162.96% |
| Research & Development | 5.16M | 8.59M | 9.19M | 8.11M | 9.27M | 9.45M | 9.33M | 9.52M | 9.16M | 8.16M | 7.69M | 7.77M | 10.79M | 6.60M | 7.22M | 7.12M | 4.50M | 5.26M | 4.79M | 4.83M | 2.38M | 1.63M | 751.47K | 709.60K | 800.00K | 1.10M | 1.40M | 2.40M | 2.80M | 2.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.32M | 11.23M | 10.41M | 9.12M | 7.44M | 9.12M | 7.88M | 7.68M | 8.79M | 8.04M | 6.74M | 6.97M | 10.08M | 9.92M | 7.35M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.74M | 13.69M | 15.14M | 13.31M | 13.63M | 8.69M | 10.50M | 10.18M | 12.40M | 12.47M | 10.43M | 10.71M | 13.68M | 11.49M | 11.04M | 11.96M | 10.78M | 9.23M | 8.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.06M | 24.93M | 25.54M | 22.43M | 21.08M | 17.81M | 18.38M | 17.85M | 21.19M | 20.51M | 17.17M | 17.67M | 23.76M | 21.40M | 18.39M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 5.10M | 8.00M | 7.20M | 8.80M | 9.80M | 7.70M | 7.90M | 0.00 |
| Other Expenses | 0.00 | 224.00K | 240.00K | 199.00K | 276.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| Operating Expenses | 22.23M | 33.74M | 34.98M | 30.74M | 30.62M | 27.56M | 28.16M | 28.49M | 31.99M | 30.41M | 24.86M | 25.44M | 30.39M | 28.00M | 25.61M | 26.55M | 22.46M | 21.87M | 19.89M | 17.04M | 11.66M | 9.21M | 3.44M | 4.22M | 4.40M | 4.80M | 6.10M | 9.60M | 10.80M | 9.60M | 9.30M | 8.40M | 9.50M | 11.80M | 9.50M | 8.50M | 500.00K |
| Cost & Expenses | 25.01M | 41.87M | 44.37M | 39.09M | 37.74M | 33.75M | 38.09M | 36.31M | 44.19M | 43.11M | 34.84M | 33.69M | 39.02M | 31.15M | 30.23M | 32.73M | 27.72M | 26.16M | 24.52M | 23.58M | 14.60M | 14.37M | 7.38M | 9.49M | 8.90M | 8.20M | 11.00M | 16.70M | 22.80M | 23.10M | 21.00M | 18.80M | 16.40M | 23.90M | 21.60M | 16.10M | 7.60M |
| Interest Income | 729.00K | 213.00K | 15.00K | 97.00K | 344.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | 24.00K | 73.27K | 119.10K | 106.03K | 74.15K | 102.96K | 127.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.00K | 10.00K | 141.00K | 476.00K | 784.00K | 504.00K | 124.00K | 63.00K | 650.00K | 2.64M | 3.28M | 3.42M | 419.00K | 269.00 | 9.33K | 280.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 409.00K | 521.00K | 557.00K | 578.00K | 673.00K | 708.00K | 1.49M | 2.31M | 3.35M | 3.53M | 2.43M | 2.80M | 3.17M | 1.64M | 1.92M | 1.84M | 1.70M | 1.66M | 1.63M | 1.34M | 667.89K | 389.88K | 486.14K | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| EBITDA | -6.57M | -9.50M | -10.55M | -16.52M | -12.05M | -7.31M | -12.66M | -7.67M | -28.43M | 4.34M | -1.77M | -3.12M | -34.42M | -4.58M | -80.66K | 6.71M | 598.07K | -4.67M | -3.00M | 1.07M | -7.42M | -8.98M | -2.05M | -1.07M | -1.60M | -2.20M | -1.80M | -3.20M | -200.00K | 2.90M | 900.00K | 5.40M | -3.80M | -200.00K | -1.40M | -4.30M | -4.40M |
| EBITDA Ratio | -37.91% | -47.38% | -30.20% | -54.48% | -38.45% | -30.30% | -30.16% | -29.06% | 1.76% | 9.97% | 2.04% | -9.13% | -25.02% | -19.76% | -7.55% | 17.62% | 2.25% | -24.21% | -15.79% | 4.60% | -113.73% | -179.60% | -42.49% | -13.75% | -23.88% | -41.51% | -55.70% | -28.32% | 12.14% | 11.89% | 4.37% | 23.48% | -31.93% | -0.92% | -7.61% | -38.39% | -44.44% |
| Operating Income | -7.69M | -13.93M | -10.73M | -9.39M | -6.40M | -8.13M | -14.17M | -9.97M | -30.08M | 815.00K | -1.78M | -5.41M | -37.19M | -6.57M | -2.12M | 4.77M | -1.10M | -6.44M | -4.75M | -267.22K | -8.08M | -9.37M | -2.54M | -1.70M | -2.20M | -2.90M | -3.10M | -5.40M | -2.20M | 1.30M | -400.00K | 4.20M | -4.50M | -2.20M | -3.20M | -4.90M | -4.90M |
| Operating Income Ratio | -44.40% | -49.85% | -31.90% | -31.61% | -20.41% | -31.73% | -50.42% | -37.85% | -72.39% | 1.86% | -5.37% | -19.14% | -129.81% | -26.74% | -7.55% | 12.71% | -4.15% | -32.65% | -24.05% | -1.15% | -123.98% | -187.40% | -52.54% | -21.76% | -32.84% | -54.72% | -39.24% | -47.79% | -10.68% | 5.33% | -1.94% | 18.26% | -37.82% | -10.14% | -17.39% | -43.75% | -181.48% |
| Total Other Income/Expenses | 699.00K | 164.00K | -512.00K | -8.18M | -7.11M | -845.00K | -106.00K | -53.00K | -2.35M | -1.67M | -5.71M | -3.92M | -395.00K | 348.27K | 109.77K | -174.60K | -434.73K | -199.28K | -3.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.60M | 0.00 | -2.70M | -300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.20M |
| Income Before Tax | -6.99M | -13.77M | -11.24M | -17.57M | -13.51M | -8.98M | -14.27M | -10.02M | -32.43M | -856.00K | -7.48M | -9.33M | -37.59M | -6.22M | -2.01M | 4.59M | -1.54M | -6.64M | -4.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 | -4.90M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.10M |
| Income Before Tax Ratio | -40.36% | -49.28% | -33.43% | -59.17% | -43.10% | -35.03% | -50.79% | -38.06% | -78.05% | -1.95% | -22.63% | -33.00% | -131.18% | -25.33% | -7.15% | 12.25% | -5.78% | -33.66% | -24.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6.33% | 0.00% | -23.79% | 4.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -300.00% |
| Income Tax Expense | 20.00K | -116.00K | 1.00K | 38.00K | 43.00K | 42.00K | -18.00K | 76.00K | 16.00K | 153.00K | 126.00K | 43.00K | 419.00K | 0.00 | -43.57K | 235.00K | 0.00 | 0.00 | 0.00 | 561.04K | 114.66K | 48.17K | 80.11K | 132.01K | 1.80M | 500.00K | -2.30M | 700.00K | 3.10M | 100.00K | 400.00K | 400.00K | 500.00K | 100.00K | 300.00K | 400.00K | 3.70M |
| Net Income | -4.85M | -13.66M | -11.25M | -17.61M | -13.55M | -9.02M | -14.26M | -10.10M | -32.45M | -1.01M | -7.61M | -9.37M | -37.59M | -6.22M | -1.97M | 4.36M | -1.54M | -6.64M | -4.76M | -828.26K | -8.20M | -9.42M | -2.62M | -1.83M | -4.00M | -3.40M | -800.00K | -6.10M | -5.30M | 900.00K | -800.00K | 3.80M | -5.00M | -2.30M | -3.50M | -5.30M | -8.60M |
| Net Income Ratio | -27.99% | -48.87% | -33.43% | -59.30% | -43.24% | -35.19% | -50.73% | -38.34% | -78.08% | -2.30% | -23.01% | -33.15% | -131.18% | -25.33% | -7.00% | 11.62% | -5.78% | -33.66% | -24.07% | -3.55% | -125.74% | -188.36% | -54.20% | -23.45% | -59.70% | -64.15% | -10.13% | -53.98% | -25.73% | 3.69% | -3.88% | 16.52% | -42.02% | -10.60% | -19.02% | -47.32% | -318.52% |
| EPS | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.44 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| EPS Diluted | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.40 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| Weighted Avg Shares Out | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.68M | 16.34M | 15.93M | 15.67M | 14.10M | 10.84M | 10.77M | 10.91M | 9.17M | 9.10M | 8.34M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 1.81M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
| Weighted Avg Shares Out (Dil) | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.69M | 16.34M | 15.93M | 15.69M | 14.10M | 10.84M | 10.80M | 10.91M | 9.17M | 9.10M | 8.55M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 2.00M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients...
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients...
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants...
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported...
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced...
iCAD to Participate in the LD Micro Main Event XVII
Nashua, New Hampshire--(Newsfile Corp. - October 16, 2024) - iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced...
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de...
iCAD, Inc. (ICAD) Q2 2024 Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants...
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported...
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion
Source: https://incomestatements.info
Category: Stock Reports